Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers - Full Text View

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

This study is currently recruiting participants.
Verified by Stanford University, June 2008

Sponsors and Collaborators:	Stanford University National Institutes of Health (NIH)
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00568490

Purpose

To correlate tumor oxygenation as measured by the Eppendorf electrode with the serum level of secreted proteins known to be induced by tumor hypoxia.

Condition	Intervention
Head and Neck Cancer Lip Neoplasms Lip Cancer Lung Cancer	Procedure: Eppendorf electrode measurements Procedure: Tumor biopsy Procedure: flabatomy

MedlinePlus related topics:

Cancer Head and Neck Cancer Lung Cancer

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Official Title:	Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Further study details as provided by Stanford University:

Estimated Enrollment:	600
Study Start Date:	September 1998

Detailed Description:

The endpoints of the study are

To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance.
To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:Newly diagnosed patients with head and neck cancer who has tumor accessible to tumor oxygenation measurement with a microelectrode.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568490

Locations


United States, California
	Stanford University School of Medicine	Recruiting
	Stanford, California, United States, 94305
	Contact: Rachel Freiberg 650-725-4777 rachelf@stanford.edu
	Contact: Cancer Clinical Trials Office (650) 498-7061
	Principal Investigator: Quynh-Thu Le
	Sub-Investigator: Amato Giaccia
	Sub-Investigator: Richard L Goode
	Sub-Investigator: Harlan Pinto
	Sub-Investigator: Dr. Billy W. Loo Jr. M.D. Ph.D.

Sponsors and Collaborators

Stanford University

National Institutes of Health (NIH)

Investigators


Principal Investigator:	Quynh-Thu Le	Stanford University

More Information

Study ID Numbers:	SU-11052007-801, 15310; CA67166, 73995, ENT0016, NCT00185822
First Received:	December 4, 2007
Last Updated:	June 10, 2008
ClinicalTrials.gov Identifier:	NCT00568490
Health Authority:	United States: Food and Drug Administration; USA:Institutional Review Board